Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Manfred Beneke"'
Autor:
Antonio Martin-Morales, Dieter Neuser, Manfred Beneke, Gilbert Bou Jaoudé, Jacques Buvat, Frans M.J. Debruyne, Alessandra Graziottin
Publikováno v:
The Journal of Sexual Medicine. 8:2831-2840
Introduction Erectile dysfunction (ED) impacts on both members of the couple. Female partners of men with ED are more likely to report reduced sexual quality of life than women whose partners do not have ED. Aim To assess vardenafil efficacy in men w
Autor:
Frank Merfort, Manfred Beneke, Ernst Ulbrich, Monika Hermanns, Tim Schneider, Jochen Gleißner
Publikováno v:
The Journal of Sexual Medicine. 8:2904-2911
Introduction The prevalence of erectile dysfunction (ED) is increased in men with metabolic syndrome compared with the general population. Aim The aim of this study was to evaluate the efficacy and safety of vardenafil vs. placebo in men who had ED a
Publikováno v:
The Journal of Sexual Medicine. 8:2912-2923
Introduction Patients and physicians consider a rapid onset of action to be an important attribute of oral pharmacotherapy for erectile dysfunction. Aim To investigate the time to onset of action of a new orodispersible tablet (ODT) formulation of va
Autor:
Ernst Ulbrich, Manfred Beneke, J. A. Rodríguez-Rivera, Silke Ewald, C. G. McMahon, M. Gittelman
Publikováno v:
International Journal of Clinical Practice. 64:594-603
Summary Aims: The aim of this study was to investigate the efficacy and safety of 10 mg vardenafil orodispersible tablet (ODT) vs. placebo in a general population of men with erectile dysfunction (ED). Methods: This was a double-blind, multicentre, r
Publikováno v:
European Urology. 54:204-212
Background Phosphodiesterase (type) 5 (PDE5) inhibitors are currently administered on demand for treatment of erectile dysfunction (ED). Once-daily dosing has been suggested to benefit patients. Objective To determine whether daily vardenafil use pro
Publikováno v:
European Urology. 53:1236-1244
Introduction Benign prostatic hyperplasia (BPH) is associated with bothersome lower urinary tract symptoms (LUTS) and reduced patient quality of life (QoL). Phosphodiesterase (type) 5 (PDE5) inhibitors such as vardenafil are commonly used for the tre
Publikováno v:
BJU International. 99:849-859
OBJECTIVE To assess the influence of vardenafil on treatment satisfaction in men with erectile dysfunction (ED) and their female partners. PATIENTS AND METHODS This was a pooled analysis of three randomized, double-blind, placebo-controlled, 12-week
Publikováno v:
Headache: The Journal of Head and Face Pain. 45:874-882
Objective: To investigate the efficacy and tolerability of almotriptan 12.5 mg in migraine patients who respond poorly to sumatriptan 50 mg. Background: Poor response to sumatriptan therapy for acute migraine attacks has been documented in the litera
Autor:
Manfred Beneke, Hartwig Schwaibold, Harin Padma-Nathan, Tiemo-Joerg Bandel, Hartmut Porst, Ernst Ulbrich, Jacques Buvat, Francesco Montorsi
Publikováno v:
The Journal of Sexual Medicine. 1:168-178
Introduction. Vardenafil, a potent and selective oral PDE5 inhibitor, is efficacious and generally well-tolerated in men with erectile dysfunction (ED). Of considerable interest to patients and physicians is an understanding of the time required afte
Publikováno v:
European Urology. 46:73-79
Objective: To determine the efficacy and tolerability of flexible dosing with vardenafil in a broad population of men with erectile dysfunction (ED). Methods: 10-week, open-label, flexible-dose study starting with vardenafil 10mg, titrating to 5mg or